Rock Springs Capital Management LP Q3 2017 Filing
Filed November 14, 2017
Portfolio Value
$2.2T
Holdings
147
Report Date
Q3 2017
Filing Type
13F-HR
All Holdings (147 positions)
| Stock | Value |
|---|---|
—MEDICINES CO | $5.3B |
ANABANAPTYSBIO INC | $5.2B |
—NABRIVA THERAPEUTICS PLC | $5.1B |
—BLUEBIRD BIO INC | $4.8B |
GBTUSDGLOBAL BLOOD THERAPEUTICS IN | $4.7B |
—MYOVANT SCIENCES LTD | $4.6B |
—ADURO BIOTECH INC | $4.4B |
EX9EXELIXIS INC | $4.2B |
MGNXMACROGENICS INC | $4.2B |
—EGALET CORP | $4.1B |
—MEDICINES CO | $3.8B |
—ALLERGAN PLC | $3.8B |
CBAYUSDCYMABAY THERAPEUTICS INC | $3.6B |
DVAXDYNAVAX TECHNOLOGIES CORP | $3.5B |
MCRB1EURSERES THERAPEUTICS INC | $3.5B |
—ZOGENIX INC | $3.5B |
BMYBRISTOL MYERS SQUIBB CO | $3.2B |
IRWDIRONWOOD PHARMACEUTICALS INC | $3.2B |
CGENCOMPUGEN LTD | $3.1B |
—DBV TECHNOLOGIES S A | $3.1B |
ITCIEURINTRA CELLULAR THERAPIES INC | $3.0B |
AGLEUSDAEGLEA BIOTHERAPEUTICS INC | $2.6B |
—CARDIOME PHARMA CORP | $2.6B |
RIGLUSDRIGEL PHARMACEUTICALS INC | $2.5B |
ZBHZIMMER BIOMET HLDGS INC | $2.5B |
—CIDARA THERAPEUTICS INC | $2.4B |
—ATYR PHARMA INC | $2.4B |
BCRXBIOCRYST PHARMACEUTICALS | $2.4B |
SG7SAGE THERAPEUTICS INC | $2.0B |
—THERAVANCE BIOPHARMA INC | $1.8B |
SCYXEURSCYNEXIS INC | $1.8B |
NVLSEURALPINE IMMUNE SCIENCES INC | $1.7B |
—MYOKARDIA INC | $1.7B |
—RADIUS HEALTH INC | $1.5B |
—DIMENSION THERAPEUTICS INC | $1.4B |
—CHIASMA INC | $1.3B |
—WRIGHT MED GROUP INC | $1.1B |
—PROTEOSTASIS THERAPEUTICS IN | $945.0M |
NVAXNOVAVAX INC | $935.0M |
—NEWLINK GENETICS CORP | $738.0M |
KALAKALA PHARMACEUTICALS INC | $571.0M |
—TANDEM DIABETES CARE INC | $411.0M |
—EGALET CORP | $384.0M |
INFIQINFINITY PHARMACEUTICALS INC | $359.0M |
—OREXIGEN THERAPEUTICS INC | $350.0M |
DAREDARE BIOSCIENCE INC | $195.0M |
ANTHANTHERA PHARMACEUTICALS INC | $155.0M |
PreviousPage 2 of 2